Sandbox Reserved 1674
From Proteopedia
(Difference between revisions)
Line 14: | Line 14: | ||
In the <scene name='87/873236/Space_fill/1'>space fill</scene> view of the enzyme, you can see the small binding pocket that is created to hold the substrate better. | In the <scene name='87/873236/Space_fill/1'>space fill</scene> view of the enzyme, you can see the small binding pocket that is created to hold the substrate better. | ||
== Other important features == | == Other important features == | ||
- | + | As previously mentioned, this enzyme does also utilize a <scene name='87/873236/Lysine_73/2'>lysine</scene> at residue 73. This is to help shuttle protons through the reaction. S170 uses it in the first part of the reaction and Glu166 is activated by this as well, and completes the reaction, as well as recreates the S170, by donating more protons. This can allow the enzyme to work multiple times and retain it's function overtime which is not good in regards to drug resistance. | |
- | + | Another interesting feature is the K234 as it doesn't actually bond with the substrate like the S130, but instead works to lower the pKa of the S130, so that it is more likely to donate a proton. | |
- | + | ||
- | + | ||
- | + | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<ref>PMID:33109613</ref> | <ref>PMID:33109613</ref> | ||
<references/> | <references/> |
Revision as of 03:27, 19 April 2021
This Sandbox is Reserved from 01/25/2021 through 04/30/2021 for use in Biochemistry taught by Bonnie Hall at Grand View University, Des Moines, USA. This reservation includes Sandbox Reserved 1665 through Sandbox Reserved 1682. |
To get started:
More help: Help:Editing |
CTX-M Beta-Lactamase
CTX-M Beta Lactamase is a class A enzyme that creates drug resistance to ampicillin and cefotaxime through. two step process of deacylation and acylation.
Function of your protein
|
References
- ↑ Soeung V, Lu S, Hu L, Judge A, Sankaran B, Prasad BVV, Palzkill T. A drug-resistant beta-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potency. J Biol Chem. 2020 Dec 25;295(52):18239-18255. doi: 10.1074/jbc.RA120.016103. Epub, 2020 Oct 26. PMID:33109613 doi:http://dx.doi.org/10.1074/jbc.RA120.016103